NCT05163301 Alcohol Research in HIV: Relapse Prevention
| NCT ID | NCT05163301 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-03-27 |
| Primary Completion | 2027-02-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2023-03-27 with a primary completion date of 2027-02-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
3-arm type 1 pilot implementation-efficacy trial for people with alcohol use disorders to examine the preliminary effectiveness and feasibility of an adapted 2-session, computerized and person delivered relapse prevention intervention.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of HIV * Aged 18 years or older * Must be enrolled in clinical care at Johns Hopkins HIV Clinic. In addition, meet the following alcohol use criteria: 1. lifetime alcohol use disorder 2. patient reported outcomes (PRO) assessment collected by the Center for AIDS Research (CFAR) Network of Clinical Systems as part of usual clinical care that show in the last 3 years: periods of no or lower risk drinking (e.g. women/men who are drinking \<11/22 drinks per week) and periods of lapse to higher levels of drinking (=\>11/22 drinks per week for women/men) 3. current PRO showing alcohol abstinence or alcohol use at \<11/22 drinks per week for women/men. Exclusion Criteria: * Acutely suicidal, homicidal, psychotic or otherwise unable to provide informed consent * Non-English speaking because interventions are currently available in English only
Contact & Investigator
Heidi Hutton, PhD
PRINCIPAL INVESTIGATOR
Johns Hopkins School of Medicine
Frequently Asked Questions
Who can join the NCT05163301 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05163301 currently recruiting?
Yes, NCT05163301 is actively recruiting participants. Contact the research team at hhutton@jhmi.edu for enrollment information.
Where is the NCT05163301 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT05163301 clinical trial?
NCT05163301 is sponsored by Johns Hopkins University. The principal investigator is Heidi Hutton, PhD at Johns Hopkins School of Medicine. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.